A Phase II Study of Chemoradiotherapy With Nimotuzumab in Unresectable Esophageal Cancer

  • days left to enroll
  • participants needed
  • sponsor
    Chinese Academy of Medical Sciences
Updated on 28 October 2021
squamous cell carcinoma
definitive treatment
esophageal cancer
chemotherapy regimen
blood urea nitrogen
esophagus cancer
intensity-modulated radiation therapy
unresectable esophageal cancer


This phase II clinical study is designed to evaluate the 1 year local tumor control rates after the targeted therapy of intensity-modulated radiation therapy synchronized chemotherapy with nimotuzumab combined with S-1 in local advanced esophageal squamous cell carcinomas based on Nutritional Risk Screening NRS2002.

Condition Chemoradiation, Esophageal Carcinoma, oesophageal carcinoma, esophagus cancer, Esophageal Diseases, Esophageal Cancer, Head and Neck Cancer, head and neck cancer, Unresectable Malignant Neoplasm, oesophageal cancer, cancer of the esophagus, Chemoradiotherapy, Nimotuzumab, Chemotherapy, Esophageal Disorders
Treatment Radiotherapy, S-1, Nimotuzumab
Clinical Study IdentifierNCT04207918
SponsorChinese Academy of Medical Sciences
Last Modified on28 October 2021


Yes No Not Sure

Inclusion Criteria

Pathologically or cytologically proven esophageal squamous cell carcinomas in patients staged as T2-4N0-1M0-1b (AJCC 6th TNM staging, M1b limited to clavicular or celiac lymph node metastasis)
Primary treatment accepted in Chinese Academy of Medical Sciences
KPS 70
NRS score 2
Cervical or thoracic esophageal cancer histologically proved esophageal cell carcinoma
Normal organ and marrow function as defined below
Hemoglobin: greater than or equal to 100g/L ;Leukocytes: greater than or equal
to 3,500 G/L; Neutrophil: greater than or equal to 1,500 G/L; Platelets
greater than or equal to 100,000/mm3 ; Creatinine within normal upper limits
BUN within normal upper limits; AST/ALT: less than or equal to 1.5 times the
upper limit; Total bilirubin: less than or equal to 1.5 times the upper limit
Alkaline phosphatase :less than or equal to 1.5 times the upper limit
Informed consent

Exclusion Criteria

Patients with other cancer history in 5 years except cervical carcinoma in situ and non-malignant melanoma skin cancer
Any prior chemotherapy or other cancer treatment prior to this protocol
With any distant metastasis in liver, lung, bone, CNS or peritoneal transplantation
History of allergic reactions attributed to contrast medium, similar chemical or biologic complex
Existing esophageal fistula, perforation and cachexia
Existing active infection such as active tuberculosis and hepatitis
Uncontrolled illness including, but not limited to, active infection, symptomatic heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness
History of myocardial infarction within the past 6 months or history of ventricular arrhythmia
Participation in other clinical trials currently or within 4 weeks of selection
Pregnant or lactating females
Clear my responses

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact



Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider


Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 



Reply by • Private

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note